TrialCancer immunology, immunotherapy : CII2012

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.

Jürgen C Becker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.